New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients
- PMID: 20385199
- DOI: 10.1016/j.fct.2010.04.007
New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients
Abstract
Anthracyclines (doxorubicin, daunorubicin, epirubicin, and idarubicin) are currently the most effective group of anti-neoplastic drugs used in clinical practice. Of these, doxorubicin (also called adriamycin) is a key chemotherapeutic agent in cancer treatment, although its use is limited as a consequence of the chronic and acute toxicity associated with this drug. The molecular mechanisms of doxorubicin account for both the anti-cancer and the toxic side effects. Many antioxidants have been assayed, with positive or negative results, to prevent the toxicity of doxorubicin. The present review has two main goals: (1) to report the latest findings regarding the molecular mechanisms of doxorubicin toxicity; (2) to update our understanding of the role of natural antioxidants in preventive therapy against doxorubicin-induced toxicity. This review provides new evidence for the chemoprevention of doxorubicin toxicity, making use of natural antioxidants - in particular vitamin E, vitamin C, coenzyme Q, carotenoids, vitamin A, flavonoids, polyphenol, resveratrol, antioxidant from virgin olive oil and selenium - and offers new insights into the molecular mechanisms of doxorubicin toxicity with respect to DNA damage, free radicals and other parameters.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Antioxidant nutrients and adriamycin toxicity.Toxicology. 2002 Oct 30;180(1):79-95. doi: 10.1016/s0300-483x(02)00383-9. Toxicology. 2002. PMID: 12324201 Review.
-
Lycopene and chemotherapy toxicity.Nutr Cancer. 2010;62(7):988-95. doi: 10.1080/01635581.2010.509838. Nutr Cancer. 2010. PMID: 20924974 Review.
-
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.Clin Cancer Res. 1997 Oct;3(10):1747-54. Clin Cancer Res. 1997. PMID: 9815559
-
Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice.Basic Clin Pharmacol Toxicol. 2005 Nov;97(5):311-9. doi: 10.1111/j.1742-7843.2005.pto_166.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 16236144
-
Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy.J Appl Toxicol. 2008 Apr;28(3):271-82. doi: 10.1002/jat.1276. J Appl Toxicol. 2008. PMID: 17582587
Cited by
-
Can Dietary Nutrients Prevent Cancer Chemotherapy-Induced Cardiotoxicity? An Evidence Mapping of Human Studies and Animal Models.Front Cardiovasc Med. 2022 Jun 29;9:921609. doi: 10.3389/fcvm.2022.921609. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35845064 Free PMC article.
-
Icariin Protects H9c2 Rat Cardiomyoblasts from Doxorubicin-Induced Cardiotoxicity: Role of Caveolin-1 Upregulation and Enhanced Autophagic Response.Nutrients. 2021 Nov 14;13(11):4070. doi: 10.3390/nu13114070. Nutrients. 2021. PMID: 34836326 Free PMC article.
-
Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells.Molecules. 2014 Dec 1;19(12):20054-72. doi: 10.3390/molecules191220054. Molecules. 2014. PMID: 25470274 Free PMC article.
-
Effects of long-acting erythropoietin analog darbepoetin-α on adriamycin-induced chronic nephropathy.Int Urol Nephrol. 2016 Feb;48(2):287-97. doi: 10.1007/s11255-015-1171-1. Epub 2015 Dec 10. Int Urol Nephrol. 2016. PMID: 26660954
-
Mitigation of doxorubicin-induced cardiotoxicity with an H2O2-Activated, H2S-Donating hybrid prodrug.Redox Biol. 2022 Jul;53:102338. doi: 10.1016/j.redox.2022.102338. Epub 2022 May 16. Redox Biol. 2022. PMID: 35609400 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical